Skip to main content

Research Repository

Advanced Search

Professor Michael Lind

Image

Michael Lind

Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies


Exploring hypoxic biology to improve radiotherapy outcomes (2022)
Journal Article
Li, C., Wiseman, L., Okoh, E., Lind, M., Roy, R., Beavis, A., & Monteiro dos Santos Pires, I. (2022). Exploring hypoxic biology to improve radiotherapy outcomes. Expert Reviews in Molecular Medicine, 24, Article E21. https://doi.org/10.1017/erm.2022.14

Ionising radiotherapy is a well-established, effective cancer treatment modality, whose efficacy has improved with the application of newer technological modalities. However, patient outcomes are governed and potentially limited by aspects of tumour... Read More about Exploring hypoxic biology to improve radiotherapy outcomes.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Browse

Advanced Search